Coherus BioSciences (CHRS) Stock Forecast, Price & News

Coherus BioSciences (NASDAQ:CHRS) Frequently Asked Questions

Is Coherus BioSciences a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences or view top-rated stocks.

When is Coherus BioSciences' next earnings date?

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Coherus BioSciences.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its quarterly earnings results on Thursday, February, 17th. The biotechnology company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.01. The biotechnology company had revenue of $73.37 million for the quarter, compared to the consensus estimate of $83.32 million. Coherus BioSciences had a negative net margin of 69.24% and a negative trailing twelve-month return on equity of 211.68%. During the same period in the previous year, the company earned $0.12 earnings per share.
View Coherus BioSciences' earnings history.

What price target have analysts set for CHRS?

5 Wall Street analysts have issued 12 month price objectives for Coherus BioSciences' shares. Their forecasts range from $15.00 to $30.00. On average, they anticipate Coherus BioSciences' stock price to reach $22.40 in the next twelve months. This suggests a possible upside of 181.8% from the stock's current price.
View analysts' price targets for Coherus BioSciences or view top-rated stocks among Wall Street analysts.

Who are Coherus BioSciences' key executives?

Coherus BioSciences' management team includes the following people:

• Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 67, Pay $1.86M) (LinkedIn Profile)
• Mr. McDavid Stilwell, Chief Financial Officer (Age 50, Pay $756k) (LinkedIn Profile)
• Mr. Vladimir Vexler Ph.D., Chief Scientific Officer (Age 64, Pay $778.28k) (LinkedIn Profile)
• Mr. Richard L. Hameister, Chief Technical Officer
• Mr. Thomas F. Fitzpatrick, Chief Legal Officer
• Cheston Turbyfill, VP of Communications
• Mr. Chris Thompson, Exec. VP of Sales
• Ms. Rebecca Sunshine, Exec. VP of HR (Age 59)
• Mr. Michael A. Fleming, Chief Strategy Officer
• Mr. Michael Chen, Sr. VP of Commercial Analytics & Trade

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Coherus BioSciences' key competitors?

Some companies that are related to Coherus BioSciences include Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Krystal Biotech (KRYS), Bavarian Nordic A/S (BVNRY), ImmunityBio (IBRX), Vaxcyte (PCVX), Valneva (VALN), Vericel (VCEL), Immunocore (IMCR), Adaptive Biotechnologies (ADPT) and Revolution Medicines (RVMD).
View all of CHRS's competitors.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.59%), Vanguard Group Inc. (6.12%), Peregrine Capital Management LLC (1.22%), Thompson Siegel & Walmsley LLC (0.91%), Northern Trust Corp (0.91%) and Citigroup Inc. (0.88%). Company insiders that own Coherus BioSciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends for Coherus BioSciences.

Which institutional investors are selling Coherus BioSciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Bank of New York Mellon Corp, Citigroup Inc., South Dakota Investment Council, Group One Trading L.P., American Century Companies Inc., SG Americas Securities LLC, and Principal Financial Group Inc.. Company insiders that have sold Coherus BioSciences company stock in the last year include Dennis M Lanfear, James Healy, and Mcdavid Stilwell.
View insider buying and selling activity for Coherus BioSciences or view top insider-selling stocks.

Which institutional investors are buying Coherus BioSciences stock?

CHRS stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Vanguard Group Inc., BlackRock Inc., Thompson Siegel & Walmsley LLC, Renaissance Technologies LLC, Royce & Associates LP, Sei Investments Co., and Connor Clark & Lunn Investment Management Ltd..
View insider buying and selling activity for Coherus BioSciences or or view top insider-buying stocks.

How do I buy shares of Coherus BioSciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $7.95.

How much money does Coherus BioSciences make?

Coherus BioSciences has a market capitalization of $615.51 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287.10 million in net income (profit) each year or ($2.730010) on an earnings per share basis.

How many employees does Coherus BioSciences have?

Coherus BioSciences employs 332 workers across the globe.

Does Coherus BioSciences have any subsidiaries?

The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..

When was Coherus BioSciences founded?

Coherus BioSciences was founded in 2010.

What is Coherus BioSciences' official website?

The official website for Coherus BioSciences is www.coherus.com.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at (650) 649-3530 or via email at [email protected].